Lachlan Hanbury Brown
Stock Analyst at William Blair
(2.02)
# 3,201
Out of 4,520 analysts
121
Total ratings
42.7%
Success rate
0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lachlan Hanbury Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics | Maintained: Buy | n/a | $5.40 | - | 12 | Jul 17, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | n/a | $58.65 | - | 13 | Jul 14, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | n/a | $7.25 | - | 27 | Jul 9, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | n/a | $5.05 | - | 19 | Jul 6, 2026 | |
| HROW Harrow | Maintained: Buy | n/a | $46.38 | - | 17 | Jul 1, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | n/a | $18.04 | - | 9 | Jun 29, 2026 | |
| OCUL Ocular Therapeutix | Maintained: Buy | n/a | $9.03 | - | 16 | Jun 18, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | n/a | $9.03 | - | 4 | May 13, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $8.85 | - | 2 | Mar 20, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | n/a | $12.87 | - | 2 | Mar 16, 2026 |
Kalaris Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: n/a
Current: $5.40
Upside: -
Tarsus Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: n/a
Current: $58.65
Upside: -
ARS Pharmaceuticals
Jul 9, 2026
Maintained: Buy
Price Target: n/a
Current: $7.25
Upside: -
LENZ Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: n/a
Current: $5.05
Upside: -
Harrow
Jul 1, 2026
Maintained: Buy
Price Target: n/a
Current: $46.38
Upside: -
Viridian Therapeutics
Jun 29, 2026
Maintained: Buy
Price Target: n/a
Current: $18.04
Upside: -
Ocular Therapeutix
Jun 18, 2026
Maintained: Buy
Price Target: n/a
Current: $9.03
Upside: -
Eupraxia Pharmaceuticals Inc.
May 13, 2026
Maintained: Buy
Price Target: n/a
Current: $9.03
Upside: -
Solid Biosciences
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $8.85
Upside: -
Zevra Therapeutics
Mar 16, 2026
Maintained: Buy
Price Target: n/a
Current: $12.87
Upside: -